Skip to content
Open access

Genetically regulated molecular mediators of phenotypic heterogeneity in autism spectrum disorder

Oct 2026 · medRxiv · 0 citations
Medicine

TL;DR

Combining within-case genome-wide association studies with xWAS nominates candidate genes mediating common-variant effects on ASD heterogeneity, provides biological insight, and suggests candidates for phenotypically stratified drug repositioning.

Abstract

Background Autism spectrum disorder (ASD) shows wide phenotypic variation, from adults without intellectual disability and with low support needs to minimally verbal children with intellectual disability and severe behavioral symptoms. Genetic studies of this heterogeneity have focused mainly on high-impact de novo variants and polygenic scores; here we investigate, at the molecular level, the role of common variants. Materials and methods We analyzed genotypic and phenotypic data from 9,332 individuals with ASD in the SPARK cohort. We considered 31 traits: six latent factors derived from the Social Communication Questionnaire and the Repetitive Behavior Scale-Revised, 22 co-occurring diagnoses, parent-reported IQ range, age at diagnosis, and age at first walking. We performed within-case genome-wide association studies (GWAS) and, for the 10 traits with evidence of SNP heritability, association analyses with genetically predicted gene and protein expression, splicing, and enhancer activity in brain and blood (xWAS). Nominated genes were tested for enrichment in biological processes, brain cell types, and developmental stages. xWAS-derived transcriptional signatures were compared with chemical perturbation signatures from CMap/LINCS L1000 to prioritize candidate drugs. Results GWAS identified seven genome-wide significant loci for five traits, including loci near GABRG3 and TENM2 associated with co-occurring sleep, feeding or toileting problems. xWAS identified seven gene-trait associations involving three phenotypes (FDR < 0.1), including CACNA1G with communication skills and NEGR1 with learning disability. GWAS and xWAS nominated different genes which however converged on synaptic transmission and gated channel activity, with preferential expression in neurons during later stages of brain development. PARP and p38 MAPK inhibitors were predicted to reverse the signatures of both social-communication and repetitive-behavior phenotypes, whereas several compound classes, including histone deacetylase inhibitors and mTOR inhibitors, were predicted to reverse the signatures of some phenotypes while mimicking those of others. Conclusion Combining within-case GWAS with xWAS nominates candidate genes mediating common-variant effects on ASD heterogeneity, provides biological insight, and suggests candidates for phenotypically stratified drug repositioning.

Read PDF

Similar papers

Review Open access Oct 2026

Prenatal genomics and autism: detectable susceptibility without validated individual-level prediction

Autism spectrum disorder (ASD) is a behaviorally defined, biologically heterogeneous neurodevelopmental condition with high heritability, estimated at 0.83 (95% CI 0.79–0.87) in Swedish population data. Large-scale exome sequencing, copy-number variant analysis, and genome-wide association studies have implicated a gro...

Ainaz Shateri · 0 citations
Open access Sep 2026

Clinical and Genetic Factors Associated With Regression in Children With Autism Spectrum Disorders.

The molecular signatures identified in regASD suggest involvement of immune and synaptic pathways, highlighting the need for further targeted research to clarify their potential therapeutic implications for this subgroup of children with ASD.

A. Maruani, Emma Delclaud, Paul Bruzeau et al. · 0 citations
Open access Sep 2026

Association of Copy Number Variations in PTEN with Autism Spectrum Disorder

Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic basis. While copy number variations (CNVs) significantly contribute to ASD risk, the specific role of individual genes within these variants remains unclear. This study investigates the contribution of CNVs in the...

Xuan-Fang Zheng, R. Tan, Yu-Ze Wang et al. · 0 citations
Review Open access Sep 2026

From genotype to phenotype: understanding the genetic basis of autism.

Recent developments have expanded the understanding of the way the genetic basis of autism manifests phenotypically, and illustrate the therapeutic potential of gene-first approaches for selected monogenic neurodevelopmental disorders.

V. Eapen, A. Stylianakis, I. Voineagu · 1 citation
Open access Oct 2026

Exome-wide rare variant genetic load is associated with cognition, intellectual disability and psychiatric disorders in population-based cohorts

Constraint-weighted rare variant load contributes measurably to cognitive and neuropsychiatric outcomes in population cohorts, particularly among people with autism spectrum disorder and related conditions.

M. Ahangari, S. Moore, J. Schleede et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.